{"prompt": "['7.2.2', 'Classification of AE', '7.2.2.1 Severity', 'For AE not included in the protocol defined grading system, the following guidelines will be', 'used to describe severity:', \"Mild: requires minimal/no treatment and do not interfere with participant's daily\", 'activities', 'Moderate: low level of inconvenience or concern with the therapeutic measures. May', 'cause some interference with functioning.', \"Severe: interrupt a participant's usual daily activity and may require systemic therapy or\", 'other treatment. Usually potentially life-threatening or incapacitating.', 'Other AE will be graded according to Common Terminology Criteria for Adverse Events version', '5.0 severity. 17', '7.2.3 Relationship to study assignment', 'For all collected AE, the causality will be determined by the temporal relationship and clinical', 'judgement of the assessor. The degree of certainty about causality will be graded as follows:', 'Definitely Related - There is clear evidence to suggest a causal relationship, and other', 'possible contributing factors can be ruled out. The clinical event, including an abnormal', 'laboratory test result, occurs in a plausible time relationship to drug administration and', 'cannot be explained by concurrent disease or other drugs or chemicals. The response to', 'withdrawal of the drug (dechallenge) should be clinically plausible. The event must be', 'pharmacologically or phenomenologically definitive, with use of a satisfactory', 'rechallenge procedure if necessary.', 'Probably Related - There is evidence to suggest a causal relationship, and the influence', 'of other factors is unlikely. The clinical event, including an abnormal laboratory test', 'result, occurs within a reasonable time after administration of the drug, is unlikely to be', 'attributed to concurrent disease or other drugs or chemicals, and follows a clinically', 'reasonable response on withdrawal (dechallenge). Rechallenge information is not', 'required to fulfill this definition.', 'Possibly Related - There is some evidence to suggest a causal relationship (e.g., the event', 'occurred within a reasonable time after administration of the trial medication). However,', \"other factors may have contributed to the event (e.g., the participant's clinical condition,\", 'other concomitant events). Although an AE may rate only as \"possibly related\" soon after', 'discovery, it can be flagged as requiring more information and later be upgraded to', '\"probably related\" or \"definitely related,\" as appropriate.', 'Unlikely to be related - A clinical event, including an abnormal laboratory test result,', 'whose temporal relationship to drug administration makes a causal relationship', 'improbable (e.g., the event did not occur within a reasonable time after administration of', 'the trial medication) and in which other drugs or chemicals or underlying disease', \"provides plausible explanations (e.g., the participant's clinical condition, other\", 'concomitant treatments).', 'Not Related - The AE is completely independent of study drug administration, and/or', 'evidence exists that the event is definitely related to another etiology. There must be an', 'Protocol Template, Version 2.0', '31']['alternative, definitive etiology documented by the clinician', '7.3', 'Reporting Procedures', '7.3.1 Adverse event reporting procedures', 'All AE will be reported to the IRB and NIA regularly and within 30 days of occurrence', '7.3.2 Serious adverse event reporting procedures', 'Any occurrence that meets a protocol-defined SAE criterion will be submitted immediately', '(within 24 hours of identification) on an SAE form to the IRB and NIA. The principal', 'investigators monitor will review and assess the SAE for regulatory reporting and potential', 'impact on study subject safety and protocol conduct.', 'At any time after completion of the study, if the investigator becomes aware of an SAE that is', 'suspected to be related to study product, the investigator will report the event to the IRB and', 'NIA.', 'All clinical trials must have a safety reporting system in place. Include details of the', 'reporting procedures and time lines, including the individual responsible for each step (e.g., the', 'Investigator, the Medical Monitor, etc.), how decisions will be made regarding determining', 'relatedness and severity, which forms should be completed, (specific information on where to', 'send this form is included), how reports will be distributed and what follow-up is required.', '7.3.3 Unexpected event reporting procedures', 'All unanticipated problems will be reported to the IRB within five days of receiving notice of the', 'event if the event requires immediate intervention to prevent serious harm to participants or', 'others. All other unanticipated problems will be reported to the IRB as soon as possible and no', 'later than ten business days from the date of the event or from the date the investigator is notified', 'of the event.', 'Investigators will promptly report (according to the above schedule) the following events to the', \"IRB if the events occur within 30 days of participants' active participation:\", 'Adverse events which in the opinion of the principal investigator are both', 'unexpected and related to the study interventions.', 'An unanticipated event related to the research that exposes individuals other than', 'the research participants (e.g., investigators, research assistants, public, etc.) to', 'potential risk', 'Information that indicates a change to the risks or potential benefits of the', 'research.', 'An interim analysis or safety monitoring report indicates that frequency or', 'magnitude of harms or benefits may be different than initially presented to the', 'IRB.', 'A paper is published from another study that shows that the risks or potential', 'Protocol Template, Version 2.0', '32']\n\n###\n\n", "completion": "END"}